UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices, including zip code)
(
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.07. Submission of Matters to a Vote of Security Holders
At the Protagonist Therapeutics, Inc. (the “Company”) 2022 Annual Meeting of Stockholders (the “Annual Meeting”) held on May 26, 2022, the stockholders voted on the four proposals listed below. The proposals are described in detail in the Company’s definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on April 13, 2022. The results of the matters voted upon at the Annual Meeting were:
Proposal 1 — To elect the two Class III directors named below to serve until the 2025 Annual Meeting of Stockholders. Each of the two named nominees was so elected, with the votes thereon as follows:
| Final Voting Results | ||||||||||||
| Nominees | For | Withheld | Broker Non-Votes | |||||||||
| Harold E. Selick, Ph.D. | 27,907,944 | 8,361,194 | 2,405,334 | |||||||||
| Bryan Giraudo | 28,108,252 | 8,160,886 | 2,405,334 | |||||||||
Proposal 2 — To approve, on an advisory basis, the compensation of the Company’s named executive officers. This proposal was approved by the requisite vote, with the votes thereon as follows:
| Final Voting Results | ||||||||||||||
| For | Against | Abstain | Broker Non-Votes | |||||||||||
| 35,832,587 | 413,371 | 23,180 | 2,405,334 | |||||||||||
Proposal 3 — To recommend, by non-binding vote, the frequency of future executive compensation votes. The votes on this proposal were as follows:
| Final Voting Results | ||||||||||||||||||
| 1 Year | 2 Years | 3 Years | Abstain | Broker Non-Votes | ||||||||||||||
| 35,578,366 | 4,924 | 683,401 | 2,447 | 2,405,334 | ||||||||||||||
Considering the strong support for an annual vote as reflected in the voting results, the Company intends to hold future advisory votes to approve executive compensation annually until the matter is again submitted to the Company’s stockholders for a vote.
Proposal 4 — To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. This proposal was approved by the requisite vote, with the votes thereon as follows:
| Final Voting Results | ||||||||||||||
| For | Against | Abstain | Broker Non-Votes | |||||||||||
| 38,667,405 | 5,575 | 1,492 | -- | |||||||||||
No other matters were submitted for stockholder action.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Protagonist Therapeutics, Inc. | ||
| Dated: June 2, 2022 | ||
| By: | /s/ Asif Ali | |
| Asif Ali | ||
| Chief Financial Officer | ||
Cover |
May 26, 2022 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | May 26, 2022 |
| Entity File Number | 001-37852 |
| Entity Registrant Name | PROTAGONIST THERAPEUTICS, INC. |
| Entity Central Index Key | 0001377121 |
| Entity Tax Identification Number | 98-0505495 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | Protagonist Therapeutics, Inc. |
| Entity Address, Address Line Two | 7707 Gateway Blvd. |
| Entity Address, Address Line Three | Suite 140 |
| Entity Address, City or Town | Newark |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 94560-1160 |
| City Area Code | 510 |
| Local Phone Number | 474-0170 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, par value $0.00001 |
| Trading Symbol | PTGX |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |